

# THE PREVALENCE OF HELICOBACTER PYLORI AMONG PATIENTS COMPLAINING FROM ABDOMINAL PAIN

*Ahed J. Al-Khatib*

Jordan University of Science and Technology, Jordan

*Ahmed Saber Abu-zaiton*

Al-albays University

---

## Abstract

Helicobacter pylori has been associated with a number of gastrointestinal disorders including gastritis, peptic ulcer disease, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. The present study was conducted to determine the prevalence of Helicobacter pylori infection among patients complaining from abdominal pain and visiting internal medicine clinics. It was also purposed to investigate the relationship between both age and sex with Helicobacter pylori infection. A retrospective study was conducted and included 101 patients with abdominal pain. The results showed that the prevalence of IgG against Helicobacter pylori infection is 85%, while about 38.6% of cases were positive for IgA against Helicobacter pylori. No significant relationships were found for IgG, IgA with age and sex ( $p$  value  $>0.05$ ). Taken together, the study showed high prevalence of H. pylori infection among patients complaining of abdominal pain. H. pylori infection is not associated significantly with age and sex.

---

**Keywords:** H.pylori, IgA, IgG, abdominal pain

## Introduction

From a microbiologic point of view, *Helicobacter pylori* (*H. pylori*) is classified as a gram negative, spiral shaped organism that colonizes the human gastric mucosa. *H. pylori* has a ubiquitous, worldwide distribution as it is claimed to be the commonest bacterial infection worldwide (Hunt, 1996). It has the ability to colonize the acid secreting portion of the stomach where it remains for long period, possibly for life (Stein, 2002; Appelmelk, 1998).

Helicobacter pylori infects over half the world's population making it one of the most successful bacterial pathogens (Giudice, 2001). Several

studies have indicated that infection rates to be highest in developing countries and gastric colonization is usually lifelong unless infection is treated (Frenck, 2003; Miehleke, 1999).

Several studies suggested that persisting *H.pylori* infection in spite of a strong cellular and humoral immune response both locally and systemically is due to the fact that natural infection does not induce protective immunity. Furthermore, infections are asymptomatic in approximately 80% of individuals, however in the remaining 20% *H. pylori* infection is associated with a number of gastrointestinal disorders including gastritis, peptic ulcer disease, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma (Enno, 1998; Ernst, 2000; Correa; Uemura, 2001).

The *H. pylori* organism has the ability to colonize the human stomach and induces long-term infection of the gastric and duodenal mucosa in children and adults. It has been estimated that the majority of peptic ulcers and 85% of gastric adenocarcinomas and in over 95% of cases of gastric mucosa-associated lymphoid tissue (MALT) lymphoma are attributed to the infection by *H.pylori* (Tolia, 1999).

Furthermore, several researchers have conducted several epidemiologic studies in various geographical regions and found the early acquirement of this infection in life especially in developing countries (Ashorn, 1996; Thomas, 1993; Bitzan, 1998).

According to studies by Wu (2001) and Rowland (1999), infection with *H. pylori* occurs via oral ingestion of the bacterium and is transmitted primarily within families during early childhood. Other routes of infection include direct transmission from person to person by saliva, vomit, or feces in industrialized countries (Wu, 2001; Parsonnet, 1999).

### **Treatment of *H.pylori***

There are certain therapeutic options for treatment of *H. pylori* infection including a combination therapy with two different antibiotics together with a proton-pump inhibitor, which is in most cases successful in eradicating the bacteria and healing ulcers (Wong, 1999).

In several conditions, it required to test for *H. pylori* if there is peptic ulcer disease, low grade gastric MALT lymphoma, after endoscopic resection of early gastric cancer, if there are first degree relatives with gastric cancer, and in certain cases of dyspepsia (Stenström, 2008) not routinely. Several ways of testing exist. One can test noninvasively for *H. pylori* infection with a blood antibody test, stool antigen test, or with the carbon urea breath test (in which the patient drinks <sup>14</sup>C- or <sup>13</sup>C-labelled urea, which the bacterium metabolizes, producing labelled carbon dioxide that can be detected in the breath). However, the most reliable method for detecting *H. pylori* infection is a biopsy check during endoscopy with a rapid urease

test, histological examination, and microbial culture. There is also a urine ELISA test with a 96% sensitivity and 79% specificity. None of the test methods are completely failsafe. Even biopsy is dependent on the location of the biopsy. Blood antibody tests, for example, range from 76% to 84% sensitivity. Some drugs can affect H. pylori urease activity and give false negatives with the urea-based tests (Stenström, 2008; Kusters, 2006).

### Study objectives

- 1- To determine the prevalence of H.pylori among patients complaining from abdominal pain.
- 2- To investigate the relationship between the IgA and IgG with sex and age.

### Methods and Subjects

This is a retrospective study. We referred to files of patients visiting internal medicine clinics. Study sample included 101 patients complaining from abdominal pain. patients were screened for H.pylori using ELIZA. Both IgG and IgA were screened for all patients. Cases were considered positive for H.pylori if the titer for IgG or IgA is  $\geq 20$ .

Statistical analysis included descriptive methods such as frequencies and percentages to describe general characteristics of participants. Chi-square test was used to explore the relationship between study variable with both IgG and IgA. Statistical significance was tested at alpha level  $\leq 0.05$ .

### Results

#### Characteristics of participants

As shown in data presented in table 1, the study included 101 participants. About 56% of participants were under the age of 35 years whereas about 44% of participants were more than 35 years. About 65% of participants were males while about 35% of participants were females. About 39% of cases were positive for IgA and about 61% of cases were positive for IgG (table 1).

**Table 1: General characteristics of participants**

Variable	Frequency	Percentage
<b>Age (years)</b>		
<35	57	56.4
$\geq 35$	44	43.6
<b>Sex</b>		
Male	66	65.3
female	35	34.7
<b>IgA</b>		
Positive	39	38.6
Negative	62	61.4
<b>IgG</b>		
Positive	86	85.1
Negative	15	14.9

### The relationship between IgA and study variables

The data presented in table 2 showed the relationship between IgA and both of age and sex. There were 22 cases (38.6%) positive for IgA under the age 35 years while there were 35 cases (61.4%) negative for IgA under 35 years. The data showed there were 17 cases (38.6%) positive for IgA over 35 years while there were 27 cases (61.4%) positive for IgA over 35 years. The relationship between IgA and age is not statistically significant (p value 0.990).

The data showed that about 41% of males were positive for IgA while about 59% of males were negative for IgA. About 34% of females were positive for IgA while about 66% of females were negative for IgA. The relationship between IgA and sex is not statistically significant (p value 0.515) (table 2).

**Table 2: the relationship between IgA and study variables**

variable	IgA		P value
	Positive	Negative	
	N (%)	N (%)	
<b>Age (years)</b>			<b>0.99</b>
<35	22 (38.6)	35 (61.4)	
≥35	17 (38.6)	27 (61.4)	
<b>Sex</b>			<b>0.515</b>
Males	27 (40.9)	39 (59.1)	
Females	12 (34.3)	23 (65.7)	

### The relationship between IgG and study variables

As shown in table 3, 86% of participants under the age 35 years were positive for IgG, and 14% were negative for IgG under the same group. About 84% of participants were positive for IgG over 35 years and about 16% were negative under the same age group. The relationship between IgG and age is not statistically significant (p value 0.793).

In regard to sex, about 85% of males and about 86% of females were positive for IgG. The relationship between sex and IgG is not statistically significant (p value 0.907).

**Table 3: The relationship between IgG and study variables**

variable	IgG		P value
	Positive	Negative	
	N (%)	N (%)	
<b>Age (years)</b>			<b>0.793</b>
<35	49 (86)	8(14)	
≥35	37 (84.1)	7 (15.9)	
<b>Sex</b>			<b>0.907</b>
Males	56 (84.8)	10 (15.2)	
Females	30 (85.7)	5 (14.3)	

## Discussion

Of 101 patient visiting internal medicine clinics of Prince Hamza ibn Hashim Hospital complaining from abdominal pain, 86 (85.1%) were positive for *H.pylori* (IgG). This finding is consistent with other studies (Tolia, 1999).

The data of the present study showed 39 cases (38.6%) were positive for IgA of *H.pylori*. our results are in line with other studies in which it has repeatedly been shown that the titers of IgA and IgG antibodies to *H pylori* in serum can be used as non-invasive tests for the presence of gastric *Hpylon* infection and gastritis (Kreuning, 1994).

It is not surprising to have no significant correlation between the titers of both IgG and IgA with age and sex (p value >0.05 for all). The reason is thought to be attributed to the clinical outcomes of the patients which are independent of age and sex.

**Conclusions:** the study showed high prevalence of *H.pylori* infection among patients complaining of abdominal pain. *H.pylori* infection is not associated significantly with age and sex.

## References:

- Appelmeik BJ, Faller G, Claeys D, Kirchner T, Vandembroucke-Grauls C (1998). Bugs on trial: the case for *Helicobacter pylori* and autoimmunity. *Trends Immunol Today*, 296: 7–11.
- Ashorn M, Miettinen A, Ruuska T, Liappala P, Maki M (1996). Seroepidemiological study of *Helicobacter pylori* infection in infancy. *Arch Dis Child*, 74:141–2.
- Bitzan MM, Gold BD, Philpott DJ, et al (1998). Inhibition of *Helicobacter pylori* and *Helicobacter mustelae* binding to lipid receptor, by bovine colostrum. *J Infect Dis*; 177(4): 955–61.
- B.C. Wong, S.K. Lam, K.C. Lai, W.H. Hu, C.K. Ching, J. Ho, S.T.Yuen, C.K. Chan, G.K. Lau, C.L. Lai (1999), Triple therapy for *Helicobacter pylori* eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study, *Aliment. Pharmacol. Ther.* 13, 303–309.
- Correa P (2003). *Helicobacter pylori* infection and gastric cancer. *Cancer Epidemiol Biomarkers Prev*, 12(3):238s–41s.
- Del Giudice G, Covacci A, Telford JL (2001). Montecucco C, Rappuoli R. The design of vaccines against *Helicobacter pylori* and their development. *Annu Rev Immunol*, 19:523–63.
- Enno A, O'Rourke J, Braye S, Howlett R, Lee A (1998). Antigen-dependent progression of mucosa-associated lymphoid tissue (MALT)-type lymphoma in the stomach, Effects of antimicrobial therapy on gastric MALT lymphoma in mice. *AmJ Pathol*, 152(6):1625–32.

- Ernst P, Gold B (2000). The disease spectrum of *Helicobacter pylori*: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. *Annu Rev Microbiol*, 54:615–40.
- Frenck Jr RW, Clemens J (2003). *Helicobacter* in the developing world. *Microbes Infect* 5(8.): 705–13.
- Hunt RH (1996). The role of *Helicobacter pylori* in pathogenesis: the spectrum of clinical outcomes. *Scand J Gastroenterol Suppl*, 220: 3–9.
- J Kreuning, J Lindeman, I Biemond, C B H W Lamers (1994). Relation between IgG and IgA antibody titres against *Helicobacter pylori* in serum and severity of gastritis in asymptomatic subjects. *J Clin Pathol*, 47:227-231
- Kusters JG, van Vliet AH, Kuipers EJ (July 2006). Pathogenesis of *Helicobacter pylori* Infection. *Clin Microbiol Rev* 19 (3): 449–90.
- Miehlke S, Thomas R, Guitierrez O, Graham D, Go M (1999). DNA fingerprinting of single colonies of *Helicobacter pylori* from gastric cancer patients suggests infection with a single predominant strain. *J Clin Microbiol*, 37(1):245–7.
- Parsonnet J, Shmueli H, Haggerty T (1999). Fecal and oral shedding of *Helicobacter pylori* from healthy infected adults. *JAMA*, 282: 2240-5.
- Rowland M, Kumar D, Daly L, O'Connor P, Vaughan D, Drumm B (1999). Low rates of *Helicobacter pylori* reinfection in children. *Gastroenterology*
- Stein M, Bagnoli F, Halenbeck R, Rappuoli R, Fantl WJ, Covacci A (2002). c-Src/Lyn kinases activate *Helicobacter pylori* cagA through tyrosine phosphorylation of the EPIYA motifs. *Mol Microbiol*, 43:971–80.
- Stenström B, Mendis A, Marshall B (2008). "Helicobacter pylori - The latest in diagnosis and treatment". *Aust Fam Physician*, 37 (8): 608–12. PMID 18704207.
- Thomas JE, Austin S, Dale A, McClean P, Harding M, Coward WA (1993). Protection by human milk IgA against *Helicobacter pylori* infection in infancy. *Lancet*, 342:121-2.
- Tolia V (1999). *Helicobacter pylori* Infection in pediatric patients. *Curr Gastroenterol Rep*, 1:308–13.
- Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al (2001). *Helicobacter pylori* infection and the development of gastric cancer. *N Engl J Med*, 345(11):784–9.
- Wu ML, Lewin KJ (2001). Understanding *Helicobacter pylori*. *HUM PATHOL*, 32:247-9.